Alkermes Looks To FDA For Approval Of Schizophrenia Drug [Seeking Alpha]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Seeking Alpha
Summary Alkermes achieved positive results from its second phase 3 study known as ENLIGHTEN-2, where those who took ALKS 3831 saw a reduction in weight gain compared to current SOC olanzapine. The company expects to file an NDA for FDA approval of ALKS 3831 treating patients with schizophrenia by mid-2019. The first phase 3 efficacy study for ALKS 3831, known as ENLIGHTEN-1, already had achieved the primary efficacy endpoint based on the PANSS compared to placebo. Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS 3831 over olanzapine is very intriguing. Alkermes may face some challenges moving forward, but the drug has a good shot at being approved regardless. Pushing The Envelope The phase 3 trial is known as ENLIGHTEN-2 a
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes to Report First Quarter Financial Results on May 1, 2024PR Newswire
- Alkermes to Report First Quarter Financial Results on May 1, 2024PR Newswire
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study [Yahoo! Finance]Yahoo! Finance
- Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
ALKS
Earnings
- 2/15/24 - Miss
ALKS
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEF
- ALKS's page on the SEC website